Tumor Biomarker Test Market could Experience Boost with New Study that Demonstrates that MicroRNAs present in Urine could serve as a Biomarker for Brain Tumor

  • Analysis
  • 31-August-2021

Diagnosing a brain tumor at an early stage is a hard feat to accomplish, mainly because people consider going through a brain CT or MRI only after neurological deficits (such as incapability of speech or immobility of limbs) act up. When finally CT or MRI detects brain tumors, it has already been too late, and they have grown too large for them to be removed completely. Such a situation results in low survival rates for the patients. Looking at these circumstances, it is believed that there is a dire need for inexpensive, easy, and accurate methods for the detection of brain tumors.
Now researchers might have overcome this hurdle as they have revealed that microRNAs are present inside the urine and have the potential to act as a biomarker for the diagnosis of brain tumors. The findings could help advance the Tumor Biomarker Test Market as it indicates that regular urine tests could lead to early detection and subsequent treatment of brain tumors. The study would not only improve the survival rate of patients but might also save lives in numerous cases. 
MicroRNAs, a.k.a tiny molecules of nucleic acid, has recently gained popularity as a diagnostic biomarker of cancerous tumors. They are known to be secreted from a number of cells and exist in the situation that is stale and undamaged, inside extracellular vesicles of biological fluids such as urine and blood. In the study, researchers discovered that microRNAs in urine could act as a biomarker for brain tumors. In addition, urine is easy to collect, and an onburden falls on the human body after supplying it.
Thus they have developed a new device consisting of 100 Million zinc oxide nanowires. The device can be easily sterilized and mass-produced and is therefore appropriate equipment for medical use. It has the ability to extract a significantly larger quantity and variety of microRNAs from one milliliter of urine in comparison to conventional methods currently existing. In addition, the team, through their analysis of microRNAs collected through the device from the patient’s urine who is suffering from brain tumors and ones that are not, discovered that numerous microRNAs collected from a brain tumor are present in urine at a stale condition.
The researchers also looked into the question of whether urinary microRNAs can serve the purpose of biomarkers within brain tumors. To come to a conclusion, they made use of their diagnostic model on the expression of microRNA’ present in the urine samples. The results demonstrated that the model has the ability to differentiate between patients with a brain tumor to those who didn’t. It was seen that the sensitivity of the device at distinguishing between this was 100% with a specificity of 97%notwithstanding the size of tumors and malignancy. Hence, the conclusion was reached that microRNAs in urine could act as a great biomarker against brain tumors.
The researchers are positive that eventually, their findings and the demonstrations of the device’s ability would lead to early diagnosis of brain cancer that is considered to be aggressive such as glioblastomas.

Other Related Reports:

Global Biomarker Test Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Global PD-L1 Biomarker Testing Market Growth (Status and Outlook) 2020-2025

Global Biomarker Market 2020 by Company, Regions, Type and Application, Forecast to 2025

Global Genomics Biomarkers Market 2021 by Company, Regions, Type and Application, Forecast to 2026